zurück

Cemiplimab (new indication: basal cell carcinoma, metastatic or locally advanced)

Subject:

  • Active Substance: Cemiplimab
  • Name: Libtayo®
  • Therapeutic area: Basal cell carcinoma
  • Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

Time table:

  • Start: 01.08.2021
  • Final decision by G-BA: 20.01.2022

Final decision:

  • Locally advanced basal cell carcinoma (laBCC): Hint for a minor additional benefit
  • Metastatic basal cell carcinoma (mBCC): No additional benefit proved